What is Pliant Therapeutics, Inc.'s earnings per share (EPS)?

Pliant Therapeutics, Inc. (PLRX) reported diluted earnings per share of -$2.43 for fiscal year 2025. This represents a 30.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pliant Therapeutics, Inc. (PLRX) Financials

PLRX

FY2025 annual

Revenue $0 YoY not available

Net Income $149.3M -29.0% YoY

EPS (Diluted) -$2.43 +30.0% YoY

Free Cash Flow -$128.7M +19.2% YoY

Market Cap $63.2M as of Oct 10, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings 0.4x on $149.3M net income, FY2025

Price / Book 0.4x on $146.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PLRX SEC filings page.

Pliant Therapeutics, Inc. (PLRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PLRX FY2025 2026-10-04

Pliant remains a research-led business: reported profits are positive, while core operations consume cash and debt financing is minimal.

In FY2023 and FY2025, net income was positive while operating income and operating cash flow were both negative; that earnings-to-cash mismatch indicates the bottom line is being shaped by items below operations, not by cash-generating commercialization. Accounting gains have not replaced development funding needs, which remain visible in the recurring operating cash outflows.

R&D reached $127.8M against $1.6M of revenue in FY2023, making research the dominant economic activity rather than a cost layered onto a mature sales base. Operating cash flow was -$116.4M that year, reinforcing the need for funding beyond operating receipts.

FY2025 ended with $225.2M of assets versus $44.0M of liabilities, so the balance sheet is primarily equity-funded. With no long-term debt and a 12.0x current ratio, reported liquidity equaled 17.9 months of the latest annual operating outflow: short-term coverage is substantial, but operations still consume cash.

Financial Health Signals

Financial health score not available

Pliant Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-5.81

Pliant Therapeutics, Inc. scores -5.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($63.2M) relative to total liabilities ($44.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Pliant Therapeutics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$0.86used

For every $1 of reported earnings, Pliant Therapeutics, Inc. used $0.86 of operating cash (-$128.3M OCF vs $149.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Pliant Therapeutics, Inc. reported an operating loss of $156.4M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$23.7M

YoY+47.6%

QoQ-10.0%

Pliant Therapeutics, Inc.'s EBITDA was -$23.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 47.6% from the same quarter a year earlier. Against the prior quarter it is down 10.0%.

Net Income

-$22.4M

YoY+48.3%

QoQ-11.6%

Pliant Therapeutics, Inc. reported -$22.4M in net income in Q2 2026. This represents an increase of 48.3% from the same quarter a year earlier. Against the prior quarter it is down 11.6%.

EPS (Diluted)

-$0.36

YoY+49.3%

QoQ-12.5%

Pliant Therapeutics, Inc. earned -$0.36 per diluted share (EPS) in Q2 2026. This represents an increase of 49.3% from the same quarter a year earlier. Against the prior quarter it is down 12.5%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$12.8M

YoY+68.6%

QoQ+33.4%

Pliant Therapeutics, Inc. recorded an outflow of $12.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 68.6% from the same quarter a year earlier. Against the prior quarter it is up 33.4%.

Cash & Debt

$24.9M

YoY-71.3%

QoQ+12.1%

5Y CAGR-6.7%

Pliant Therapeutics, Inc. held $24.9M in cash against $0 in long-term debt as of Q2 2026.

Shares Outstanding

62M

YoY+0.9%

QoQ0.0%

5Y CAGR+11.5%

Pliant Therapeutics, Inc. had 62M shares outstanding in Q2 2026. This represents an increase of 0.9% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-15.2%

YoY+4.4pp

QoQ-3.1pp

Pliant Therapeutics, Inc.'s ROE was -15.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$16.7M

YoY-48.0%

QoQ+23.1%

Pliant Therapeutics, Inc. invested $16.7M in research and development in Q2 2026. This represents a decrease of 48.0% from the same quarter a year earlier. Against the prior quarter it is up 23.1%.

Capital Expenditures

YoY-100.0%

Pliant Therapeutics, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

PLRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	N/A	$0	$0-100.0%	$1.6M-83.7%	$9.7M+27.9%	$7.6M-81.9%	$41.8M-26.7%	$57.1M
R&D Expenses	N/A	$109.2M-35.5%	$169.3M+32.5%	$127.8M+31.8%	$96.9M+25.0%	$77.5M+17.2%	$66.2M+39.8%	$47.4M
SG&A Expenses	N/A	$47.2M-20.0%	$59.1M+1.9%	$57.9M+45.0%	$39.9M+45.0%	$27.6M+59.6%	$17.3M+58.0%	$10.9M
Operating Income	N/A	-$156.4M+31.5%	-$228.4M-24.0%	-$184.1M-44.8%	-$127.2M-30.4%	-$97.5M-134.2%	-$41.6M-3283.0%	-$1.2M
EBITDA	N/A	-$154.7M+31.6%	-$226.2M-24.1%	-$182.3M-45.4%	-$125.4M-30.6%	-$96.0M-138.0%	-$40.3M-34082.2%	-$118K
Interest Expense	N/A	$2.6M-15.4%	$3.0M+138.7%	$1.3M+60.2%	$791K	$0	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	$149.3M-29.0%	$210.3M+30.4%	$161.3M+230.8%	-$123.3M-26.8%	-$97.3M-134.2%	-$41.5M-6482.1%	-$631K
EPS (Basic)	N/A	-$2.43+30.0%	-$3.47-26.2%	-$2.75+6.5%	-$2.94-8.5%	-$2.71-39.0%	-$1.95+53.8%	-$4.22
EPS (Diluted)	-$1.49	-$2.43+30.0%	-$3.47-26.2%	-$2.75+6.5%	-$2.94-8.5%	-$2.71	-$1.95	-$4.22
Diluted Shares (Avg)	N/A	61M+1.4%	61M+3.1%	59M+39.8%	42M+17.2%	36M	21M	2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
R&D Expenses	$16.7M-48.0%	$13.6M-68.7%	N/A	$17.9M-62.4%	$32.2M-29.4%	$43.4M+16.9%	N/A	$47.8M+47.7%
SG&A Expenses	$7.1M-46.7%	$8.2M-47.2%	N/A	$10.3M-27.6%	$13.4M-10.8%	$15.5M+1.7%	N/A	$14.3M-7.1%
Operating Income	-$23.9M+47.7%	-$21.8M+63.1%	N/A	-$28.3M+54.4%	-$45.6M+24.8%	-$58.9M-12.5%	N/A	-$62.0M-30.0%
EBITDA	-$23.7M+47.6%	-$21.5M+63.2%	N/A	-$27.9M+54.7%	-$45.2M+24.7%	-$58.5M-12.7%	N/A	-$61.5M-30.4%
Interest Expense	$0-100.0%	$0-100.0%	N/A	$815K-7.1%	$809K-6.8%	$799K+79.6%	N/A	$877K+176.7%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$22.4M+48.3%	-$20.0M+64.3%	N/A	-$26.3M+54.5%	-$43.3M+22.5%	-$56.2M-19.6%	N/A	-$57.8M-39.2%
EPS (Basic)	-$0.36+49.3%	-$0.32+65.2%	-$0.38+53.1%	-$0.43+54.7%	-$0.71+22.8%	-$0.92-17.9%	-$0.81-17.4%	-$0.95-35.7%
EPS (Diluted)	-$0.36+49.3%	-$0.32+65.2%	-$0.38+53.1%	-$0.43+54.7%	-$0.71+22.8%	-$0.92-17.9%	-$0.81-17.4%	-$0.95-35.7%
Diluted Shares (Avg)	62M+0.9%	62M+0.9%	N/A	61M+1.1%	61M+1.7%	61M+1.7%	N/A	61M+1.7%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

PLRX Balance Sheet

PLRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$225.2M-43.3%	$396.9M-22.5%	$512.2M+46.1%	$350.6M+58.5%	$221.2M-25.1%	$295.5M+148.2%	$119.1M
Current Assets	$196.4M-45.8%	$362.3M-28.3%	$505.5M+48.5%	$340.3M+62.5%	$209.4M-28.0%	$290.8M+159.8%	$111.9M
Cash & Equivalents	$45.4M-36.2%	$71.2M+12.6%	$63.2M+87.7%	$33.7M-34.8%	$51.7M+1.5%	$50.9M-40.7%	$85.8M
Short-Term Investments	$145.5M-48.9%	$284.5M-34.0%	$431.0M+44.9%	$297.5M+99.8%	$148.9M-34.1%	$226.0M+1232.1%	$17.0M
Accounts Receivable	N/A	N/A	$0-100.0%	$2.0M-0.8%	$2.0M-78.5%	$9.3M+31.6%	$7.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$44.0M-52.6%	$92.9M+140.7%	$38.6M+3.5%	$37.3M+68.2%	$22.2M+77.7%	$12.5M-93.6%	$195.4M
Current Liabilities	$16.4M-50.7%	$33.2M+16.5%	$28.5M+19.3%	$23.9M+42.1%	$16.8M+45.1%	$11.6M+41.9%	$8.2M
Non-Current Liabilities	$27.7M-53.6%	$59.6M+493.3%	$10.1M-24.7%	$13.4M+150.9%	$5.3M+514.9%	$866K-99.5%	$187.2M
Long-Term Debt	$0-100.0%	$30.2M+200.5%	$10.1M+1.3%	$9.9M	$0	N/A	N/A
Total Equity	$181.2M-40.4%	$304.1M-35.8%	$473.6M+51.1%	$313.3M+57.4%	$199.1M-29.7%	$283.1M+471.0%	-$76.3M
Retained Earnings	-$859.4M-21.0%	-$710.1M-42.1%	-$499.7M-47.7%	-$338.4M-57.3%	-$215.1M-82.5%	-$117.8M-54.4%	-$76.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$189.9M-36.7%	$202.6M-41.2%	$225.2M-43.3%	$276.6M-37.9%	$299.8M-38.0%	$344.8M-33.9%	$396.9M-22.5%	$445.7M-17.5%
Current Assets	$163.1M-39.0%	$174.9M-43.8%	$196.4M-45.8%	$245.6M-40.1%	$267.4M-40.2%	$311.2M-36.5%	$362.3M-28.3%	$410.0M-23.3%
Cash & Equivalents	$24.9M-71.3%	$22.2M-75.9%	$45.4M-36.2%	$93.7M+17.7%	$86.8M+8.0%	$91.9M-19.6%	$71.2M+12.6%	$79.6M+38.0%
Short-Term Investments	$133.2M-24.3%	$148.7M-30.4%	$145.5M-48.9%	$148.1M-54.4%	$176.1M-50.6%	$213.7M-41.9%	$284.5M-34.0%	$324.9M-30.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$43.0M-46.1%	$37.4M-57.3%	$44.0M-52.6%	$76.3M-23.6%	$79.7M-12.4%	$87.6M+4.0%	$92.9M+140.7%	$99.8M+166.8%
Current Liabilities	$16.5M-19.9%	$10.4M-63.3%	$16.4M-50.7%	$17.6M-55.9%	$20.6M-33.4%	$28.2M-7.2%	$33.2M+16.5%	$40.0M+45.8%
Non-Current Liabilities	$26.5M-55.2%	$27.1M-54.4%	$27.7M-53.6%	$58.7M-2.0%	$59.2M-1.6%	$59.4M+10.2%	$59.6M+493.3%	$59.9M+497.7%
Long-Term Debt	$0-100.0%	$0-100.0%	$0-100.0%	$30.4M+1.0%	$30.4M+1.0%	$30.3M+0.9%	$30.2M+200.5%	$30.1M+200.8%
Total Equity	$146.9M-33.2%	$165.2M-35.8%	$181.2M-40.4%	$200.3M-42.1%	$220.1M-44.0%	$257.2M-41.2%	$304.1M-35.8%	$345.8M-31.3%
Retained Earnings	-$901.8M-11.4%	-$879.4M-14.8%	-$859.4M-21.0%	-$835.8M-26.6%	-$809.5M-34.3%	-$766.2M-40.2%	-$710.1M-42.1%	-$660.3M-44.0%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

PLRX Cash Flow Statement

PLRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$70.9M	-$128.3M+17.5%	-$155.5M-33.6%	-$116.4M-23.0%	-$94.6M-25.4%	-$75.4M-102.4%	-$37.3M-1255.3%	-$2.8M
Depreciation & Amortization	N/A	$1.7M-20.2%	$2.1M+15.4%	$1.8M+1.0%	$1.8M+18.8%	$1.5M+17.2%	$1.3M+17.7%	$1.1M
Stock-Based Compensation	N/A	$26.2M-30.3%	$37.6M-15.4%	$44.5M+96.8%	$22.6M+116.5%	$10.4M+168.0%	$3.9M+113.0%	$1.8M
Capital Expenditures	$0	$374K-90.3%	$3.8M+317.8%	$921K-47.7%	$1.8M-9.9%	$2.0M+27.5%	$1.5M+58.9%	$964K
Free Cash Flow	-$70.9M	-$128.7M+19.2%	-$159.4M-35.9%	-$117.3M-21.7%	-$96.4M-24.5%	-$77.4M-99.5%	-$38.8M-944.8%	-$3.7M
Investing Cash Flow	$41.1M	$134.3M-4.3%	$140.3M+210.5%	-$127.0M+15.4%	-$150.2M-303.8%	$73.7M+135.0%	-$210.9M-1076.0%	-$17.9M
Financing Cash Flow	-$32.1M	-$31.7M-237.1%	$23.1M-91.6%	$274.4M+21.0%	$226.9M+8877.2%	$2.5M-98.8%	$213.2M+368.2%	$45.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$12.8M+68.5%	-$19.2M+60.6%	-$17.8M+62.7%	-$21.1M+34.7%	-$40.6M+10.4%	-$48.9M-61.4%	-$47.7M-89.9%	-$32.3M+10.9%
Depreciation & Amortization	$200K-50.0%	$264K-41.1%	$365K-20.3%	$400K-20.0%	$400K-33.3%	$448K-12.7%	$458K-1.3%	$500K0.0%
Stock-Based Compensation	$4.2M-34.4%	$4.3M-52.3%	N/A	$6.4M-27.9%	$6.4M-40.0%	$8.9M-7.8%	N/A	$8.9M-14.1%
Capital Expenditures	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$112K-91.0%	$262K-82.4%	$209K+242.6%	$896K+853.2%
Free Cash Flow	-$12.8M+68.6%	-$19.2M+60.9%	-$17.8M+62.8%	-$21.1M+36.4%	-$40.7M+12.5%	-$49.1M-54.7%	-$47.9M-90.2%	-$33.2M+8.7%
Investing Cash Flow	$15.5M-56.4%	-$4.1M-105.9%	$1.8M-95.5%	$27.9M-9.8%	$35.5M+231.6%	$69.1M+16.1%	$39.1M+22.6%	$31.0M-19.1%
Financing Cash Flow	$0	$74K-85.1%	-$32.3M-31734.3%	$72K-86.7%	$0-100.0%	$498K-97.7%	$102K-53.4%	$543K-22.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PLRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Margin	N/A	N/A	-11654.8%	-1313.4%	-1288.1%	-99.6%-97.4pp	-2.2%
Net Margin	N/A	N/A	10208.9%	-1273.3%	-1284.5%	-99.3%-98.2pp	-1.1%
Return on Equity	82.4%+13.2pp	69.2%+35.1pp	34.1%+73.4pp	-39.4%+9.5pp	-48.9%-34.2pp	-14.7%	N/A
Return on Assets	66.3%+13.3pp	53.0%+21.5pp	31.5%+66.7pp	-35.2%+8.8pp	-44.0%-29.9pp	-14.1%-13.5pp	-0.5%
Current Ratio	12.00+1.1x	10.91-6.8x	17.72+3.5x	14.23+1.8x	12.44-12.6x	25.07+11.4x	13.69
Debt-to-Equity	0.00-0.1x	0.10+0.1x	0.020.0x	0.030.0x	0.000.0x	0.04	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.030.0x	0.03-0.1x	0.14-0.3x	0.48
FCF Margin	N/A	N/A	-7422.9%	-995.3%	-1022.1%	-92.8%-86.3pp	-6.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-15.2%+4.4pp	-12.1%+9.7pp	N/A	-13.1%+3.6pp	-19.7%-5.5pp	-21.8%-11.1pp	N/A	-16.7%-8.5pp
Return on Assets	-11.8%+2.7pp	-9.9%+6.4pp	N/A	-9.5%+3.4pp	-14.4%-2.9pp	-16.3%-7.3pp	N/A	-13.0%-5.3pp
Current Ratio	9.90-3.1x	16.89+5.9x	12.00+1.1x	13.93+3.7x	12.99-1.5x	11.03-5.1x	10.91-6.8x	10.26-9.2x
Debt-to-Equity	0.00-0.1x	0.00-0.1x	0.00-0.1x	0.15+0.1x	0.14+0.1x	0.120.0x	0.10+0.1x	0.09+0.1x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Pliant Therapeutics, Inc. PLRX	FY2025	$0	$149.3M	N/A	$63.2M	—
Surrozen, Inc. SRZN	FY2025	$3.5M	-$242.0M	N/A	$349.0M	42/100
Atossa Therapeutics, Inc. ATOS	FY2025	N/A	-$34.8M	N/A	$24.3M	—
HilleVax, Inc. HLVX	FY2024	N/A	-$147.3M	N/A	$104.8M	—
Cassava Sciences, Inc. SAVA	FY2025	N/A	-$91.0M	N/A	$115.0M	—
MacroGenics, Inc. MGNX	FY2025	$149.5M	-$75K	-0.1%	$238.2M	57/100

Where Pliant Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Pliant Therapeutics, Inc.'s annual revenue?

Pliant Therapeutics, Inc. (PLRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Pliant Therapeutics, Inc. profitable?

Yes, Pliant Therapeutics, Inc. (PLRX) reported a net income of $149.3M in fiscal year 2025.

What is Pliant Therapeutics, Inc.'s EBITDA?

Pliant Therapeutics, Inc. (PLRX) had EBITDA of -$154.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Pliant Therapeutics, Inc. have?

As of fiscal year 2025, Pliant Therapeutics, Inc. (PLRX) had $45.4M in cash and equivalents against $0 in long-term debt.

What is Pliant Therapeutics, Inc.'s return on equity (ROE)?

Pliant Therapeutics, Inc. (PLRX) has a return on equity of 82.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pliant Therapeutics, Inc.'s free cash flow?

Pliant Therapeutics, Inc. (PLRX) recorded an outflow of $128.7M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pliant Therapeutics, Inc.'s operating cash flow?

Pliant Therapeutics, Inc. (PLRX) recorded an outflow of $128.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Pliant Therapeutics, Inc.'s total assets?

Pliant Therapeutics, Inc. (PLRX) had $225.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pliant Therapeutics, Inc.'s capital expenditures?

Pliant Therapeutics, Inc. (PLRX) invested $374K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pliant Therapeutics, Inc. spend on research and development?

Pliant Therapeutics, Inc. (PLRX) invested $109.2M in research and development during fiscal year 2025.

How many shares does Pliant Therapeutics, Inc. have outstanding?

Pliant Therapeutics, Inc. (PLRX) had 62M shares outstanding as of fiscal year 2025.

What is Pliant Therapeutics, Inc.'s current ratio?

Pliant Therapeutics, Inc. (PLRX) had a current ratio of 12.00 as of fiscal year 2025, which is generally considered healthy.

What is Pliant Therapeutics, Inc.'s debt-to-equity ratio?

Pliant Therapeutics, Inc. (PLRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pliant Therapeutics, Inc.'s return on assets (ROA)?

Pliant Therapeutics, Inc. (PLRX) had a return on assets of 66.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pliant Therapeutics, Inc.'s P/E ratio?

Pliant Therapeutics, Inc. (PLRX) trades at 0.4x earnings, its market capitalization divided by net income of $149.3M net income, FY2025. The market capitalization is $63.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pliant Therapeutics, Inc.'s price-to-sales ratio?

Pliant Therapeutics, Inc. (PLRX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $63.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Pliant Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Pliant Therapeutics, Inc. (PLRX) held $190.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $128.3M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Pliant Therapeutics, Inc.'s Altman Z-Score?

Pliant Therapeutics, Inc. (PLRX) has an Altman Z-Score of -5.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pliant Therapeutics, Inc.'s Piotroski F-Score?

Pliant Therapeutics, Inc. (PLRX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pliant Therapeutics, Inc.'s earnings high quality?

For every $1 of reported earnings, Pliant Therapeutics, Inc. (PLRX) used $0.86 of operating cash (-$128.3M OCF vs $149.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pliant Therapeutics, Inc. cover its interest payments?

Pliant Therapeutics, Inc. (PLRX) reported an operating loss of $156.4M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.